Catalog No.
DHJ24001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
Concentration
2.18 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8NBP7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
REGN727, SAR-236553, CAS: 1245916-14-6
Clone ID
Alirocumab
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome, PMID: 30403574
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES, PMID: 31707788
Alirocumab for hypercholesterolaemia, PMID: 30765907
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome, PMID: 31948641
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, PMID: 25773378
Effect of Alirocumab on Mortality After Acute Coronary Syndromes, PMID: 31117810
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial, PMID: 31272931
Alirocumab, PMID: 31643517
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab, PMID: 27231792
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial, PMID: 30428396
Alirocumab, PMID: 29999811
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial, PMID: 32646561
Alirocumab for low-density lipoprotein cholesterol lowering, PMID: 30499328
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol, PMID: 32035487
Alirocumab for the treatment of hypercholesterolemia, PMID: 28277798
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial, PMID: 30898609
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial, PMID: 32381160
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial, PMID: 33051646
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery, PMID: 31466614
Alirocumab for the treatment of hypercholesterolaemia, PMID: 28395555
An evaluation of alirocumab for the treatment of hypercholesterolemia, PMID: 26563849
Alirocumab in Polyvascular Atherosclerotic Disease, PMID: 31948655
Alirocumab: A Review in Hypercholesterolemia, PMID: 26935836
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial, PMID: 32223446
Reply: Alirocumab in Polyvascular Atherosclerotic Disease, PMID: 31948656
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial, PMID: 31707832
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial, PMID: 32820320
Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review, PMID: 29171769
Alirocumab's Price Reduction, PMID: 30354510
Alirocumab as add-on therapy to statins: current evidence and clinical potential, PMID: 29792380
Alirocumab: First Global Approval, PMID: 26370210
Alirocumab (Praluent) for Treatment of Hyperlipidemia, PMID: 27548598
Alirocumab after Acute Coronary Syndrome, PMID: 31116932
Alirocumab after Acute Coronary Syndrome, PMID: 31116931
Alirocumab after Acute Coronary Syndrome, PMID: 31116930
Alirocumab after Acute Coronary Syndrome, PMID: 31116933
Alirocumab after Acute Coronary Syndrome, PMID: 31116929
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I, PMID: 27639753
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial, PMID: 25687353
Alirocumab after Acute Coronary Syndrome. Reply, PMID: 31116934
Alirocumab -- Addendum to Commission A15-47 [Internet], PMID: 29144668
Scleritis With Uveal Effusion From Alirocumab, PMID: 32150753
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia, PMID: 26330422
Alirocumab (Praluent) to lower LDL-Cholesterol, PMID: 26262881
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial, PMID: 25440796
Alirocumab: targeting PCSK9 to treat hypercholesterolemia, PMID: 26798848
PCSK9 inhibitors: clinical evidence and implementation, PMID: 30420622
The Evolving Future of PCSK9 Inhibitors, PMID: 30012326
Efficacy and safety of different doses of alirocumab in reducing low-density lipoprotein cholesterol levels: a network meta-analysis, PMID: 30782243
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies, PMID: 31706300
For research use only. Not for human or drug use.
